Cost should be the principal determinant of choice of erythropoiesis-stimulating agent in chronic haemodialysis patients.

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)
Original languageEnglish
Pages (from-to)c14-9-c19
Number of pages11
JournalNephron. Clinical practice
Volume107(1)
Issue number1
DOIs
Publication statusPublished - Sep 2007

ASJC Scopus subject areas

  • Nephrology

Cite this